FOSTER CITY, Calif. & NEW YORK--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and the Cardiovascular Research Foundation (CRF) today announced the initiation of RIVER-PCI (Ranolazine for Incomplete VEssel Revascularization post-PCI), a Phase 3 clinical trial evaluating the utility of ranolazine to prevent major adverse cardiovascular events (MACE) in patients with a history of chronic angina who have incomplete revascularization following percutaneous coronary intervention (PCI). RIVER-PCI will enroll 2,600 patients at approximately 200 investigative centers in the United States, Canada, Europe and Israel.
